Retatrutide: what the Phase 1, Phase 2, and Phase 3 data have measured.

The short version

Retatrutide is an investigational weight-loss and diabetes drug that works by activating three hormone receptors at the same time — GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon. That makes it a "triple agonist." It is not approved by the FDA or any other regulator as of mid-2026. Eli Lilly developed it, and it is currently in large Phase 3 clinical trials called TRIUMPH.

In Phase 2 studies, retatrutide produced the largest weight reductions ever measured in a drug trial — up to 24.2% of body weight at 48 weeks ^[1]. That is a meaningful step beyond what single or dual incretin agents have produced in comparable studies. Phase 3 data are beginning to appear: the first trial in type 2 diabetes (TRANSCEND-T2D-1) showed retatrutide 12 mg reduced HbA1c (a marker of blood sugar control over three months) by 1.94% and body weight by 15.3% versus placebo ^[12].

This site documents the published clinical trial record. It describes what the studies found, what the safety signals are, and what is still unknown — including a question that matters to anyone following this drug: what the evidence says about retatrutide results after stopping treatment and how long does retatrutide take to work in trials. What people report — including reported downsides — is on the Retatrutide effects page.

What does retatrutide do

Retatrutide activates three distinct metabolic receptors in a single injection. The GLP-1 arm suppresses appetite and slows gastric emptying (reducing how fast food moves through the stomach). The GIP arm enhances glucose-driven insulin release and influences fat tissue. The glucagon arm increases energy expenditure — the number of calories the body burns at rest — and accelerates hepatic (liver) lipid breakdown.

The combination produces larger caloric deficits than GLP-1 or GIP/GLP-1 dual agonism alone. In a 48-week Phase 2 obesity trial (n=338 adults), the 12 mg once-weekly dose produced a mean body-weight reduction of 24.2% versus 2.1% for placebo ^[1]. In a 36-week Phase 2 trial in type 2 diabetes (n=281), 12 mg reduced HbA1c by 2.02% at 24 weeks and body weight by 16.94% at 36 weeks ^[2]. A dedicated Phase 2a substudy found 12 mg reduced liver fat (measured by MRI-PDFF, a non-invasive imaging technique) by 82.4% at 24 weeks in participants with MASLD (metabolic dysfunction-associated steatotic liver disease, formerly known as fatty liver disease), with 86% reaching normal liver-fat levels ^[5].

These are Phase 2 findings from randomized controlled trials. They establish that the drug is highly active in the studied populations. They do not establish long-term safety, durability, or effectiveness outside those trial conditions — all of which are what the Phase 3 TRIUMPH program is designed to measure.

How does retatrutide work

Retatrutide is a 39-amino-acid synthetic peptide built on a GIP-based backbone. A C20 fatty-diacid chain is attached to extend its half-life by binding it to albumin in the bloodstream. The Phase 1b pharmacokinetic study measured a half-life of approximately 6 days, which is what makes once-weekly subcutaneous dosing practical ^[4].

At the receptor level, cryo-EM (cryo-electron microscopy, a technique that images molecules at near-atomic resolution) has resolved retatrutide's binding geometry at all three targets. It is approximately 8.9 times more potent at the GIP receptor than native GIP, and 0.3× to 0.4× at the glucagon and GLP-1 receptors compared to their endogenous hormones — a deliberate design choice to maximize appetite and weight effects while limiting glucagon-driven hyperglycemia risk ^[3].

All three targets are class-B GPCRs (G protein-coupled receptors, cell-surface proteins that translate hormone signals into intracellular responses via cAMP/PKA signaling). The downstream effect on energy balance — via appetite, insulin secretion, and energy expenditure — is larger than any single pathway can produce. A 2024 review described the tri-agonist approach as potentially rivaling bariatric surgery for weight loss magnitude ^[11].

Is retatrutide fda approved

Retatrutide is not FDA-approved. It is not approved by any regulatory agency worldwide as of mid-2026. It remains an investigational compound — one that has completed Phase 1 and Phase 2 trials and entered Phase 3, but has not yet been reviewed or authorized for prescription use.

The Phase 3 program (TRIUMPH) includes multiple trials across obesity, type 2 diabetes, cardiovascular outcomes, chronic kidney disease, and an active-comparator trial versus tirzepatide. These trials must complete, and Eli Lilly must submit a regulatory dossier for review, before any approval is possible. Based on current trial timelines, a potential submission would not come before late 2026 at the earliest, and approval would follow after that review process.

The Retatrutide research page covers the TRIUMPH program in detail.

Retatrutide availability

Retatrutide is not available as a prescription drug, a compounded drug, or through any legal commercial channel as of mid-2026. It exists as a regulated investigational product administered only within enrolled clinical trials.

A gray market for research-labeled retatrutide does exist. Vials sold through research channels cannot be confirmed to contain authentic retatrutide at stated concentrations — independent analyses of similar gray-market peptides have found truncated sequences, racemized amino acids, or entirely different compounds. Without sterility testing and endotoxin assays, unverified injectable materials carry contamination risks including sepsis. The FDA issued warning letters to retatrutide vendors in 2025 citing Federal Food, Drug, and Cosmetic Act violations.

This site is an editorial digest of the published clinical trial literature. It does not sell, distribute, or direct toward any product source.

When will retatrutide be available

The timeline depends on Phase 3 completion and regulatory review. The TRANSCEND-T2D-1 Phase 3 trial in type 2 diabetes has reported results, published in The Lancet in 2026 ^[12]. Additional TRIUMPH trials — including obesity, cardiovascular outcomes, and CKD outcomes — remain ongoing as of mid-2026.

If Phase 3 trials complete on schedule and Eli Lilly files for FDA review, an approval decision could plausibly occur in 2027 or 2028 — but regulatory timelines are not guarantees, and the agency may request additional data. There is no confirmed availability date. This site documents what the published data says; it does not track Eli Lilly's commercial pipeline.